Form 4: Lyra Therapeutics Director James R. Tobin Reports Stock Option Grant
SEC Form 4 Filing
Director James R. Tobin reports the acquisition of stock options in Lyra Therapeutics, Inc.
Summary
- James R. Tobin, a director of Lyra Therapeutics, Inc., reported a transaction involving stock options.
- On June 13, 2024, Tobin acquired 30,000 stock options with an exercise price of $0.31.
- These options vest on the earlier of June 13, 2025, or the day before the next annual meeting of stockholders after the grant date, contingent on continued service as a non-employee director.
- Following the transaction, Tobin directly owns 30,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock option grant, neither particularly positive nor negative.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of the company's directors.
Stakeholder Impact
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of stock option grant |
| 06/13/2025 | First possible vesting date of the stock options |
| 06/12/2034 | Expiration date of the stock options |
| 06/14/2024 | Date of Form 4 filing |
Keywords
Lyra Therapeutics, Director, Stock Options, Form 4, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.